WIPRO
10.3.2021 15:32:07 CET | Business Wire | Pressemeddelelse
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), en førende global virksomhed inden for informationsteknologi, konsulentvirksomhed og forretningsprocesser annoncerede i dag udnævnelsen af Pierre Bruno som administrerende direktør, Europa.
I denne rolle vil Bruno lede Wipro’s forretning i seks forskellige regioner på tværs af Europa. Denne udnævnelse, er en dristig indikation af virksomhedens fortsatte investering og fokus på det europæiske marked, som bygger på Wipros fremdrift i hele regionen i de seneste år.
“Pierre har mere end 25 års erfaring inden for IT-infrastruktur, konsulent og servicesektoren. Han har leder virksomheder i både hypervækstmiljøer og inden for teknologi transformation. Med hans erfaring i ledelse af store teams er han godt positioneret til at føre Wipros vækstrejse videre i Europa,” sagde Thierry Delaporte, CEO & MD, Wipro Limited.
“Jeg er begejstret for muligheden for at lede Wipro’s aktiviteter på det europæiske marked, der byder på fantastiske muligheder for vækst. Jeg ser frem til at videreudvikle samt fremme vores engagement over for vores europæiske kunder, når de navigerer i deres forretningstransformation og fortsætter med at udvikle sig i en digital verden,” sagde Pierre Bruno , Administrerende direktør, Europa .
Bruno kommer til Wipro fra DXC Technology, hvor han var vicepræsident og administrerende direktør for Sydeuropa, ansvarlig for alle dele af forretningen, herunder rådgivning, integration, apps, cloud og cybersikkerhed. Bruno arbejdede også for Dell i 14 år i flere roller i Asien, Stillehavsområdet, Japan og EMEA. Han spillede en central rolle i Dells transformation fra at sælge hardware til at blive en vigtig aktør inden for levering af infrastrukturløsninger.
Bruno har en kandidatgrad i forretningsadministration (MBA) med hovedfag i Marketing og økonometri fra HEC Graduate School i Paris. Han har også en kandidatgrad i bioteknik.
Wipro’s forpligtelse i Europa
Wipro’s europæiske tilstedeværelse omfatter seks regioner, bestående af Storbritannien og Irland, Tyskland, Schweiz, Norden, Benelux og Sydeuropa, samt tre near-shore leverancecentre og omfatter en bred vifte af betydelige kunder på tværs af brancher, hvoraf mange bliver supporteret af Wipro på deres teknologiste vækst samt transformationsrejse..
Nogle af de seneste aftaler i Europa omfatter
- En vigtig strategisk digital og IT-partnerskabsaftale med METRO AG, en førende global grossistvirksomhed.
- Et engagement med den Finland-baserede producent af ren energi Fortum for at hjælpe med at opgradere applikationslandskabet samt tilhørende serviceintegration,.
- En flerårig global aftale om automotive engineering services med den italienske bilgigant Marelli.
- I Tyskland arbejder vi sammen med Telefónica Germany/O2 og dets bredere økosystem til at transformere deres forretningssupportsystemer og tilhørende kvalitetssikring for at sikre en optimal kundeoplevelse og vækst i B2B-markedssegmentet.
- En strategisk, flerårig infrastruktur’s modernisering og digital transformations services fra det tyskbaserede energiselskab E.ON.
Om Wipro Limited
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) er en førende global virksomhed inden for informationsteknologi, rådgivning og forretningsprocesser. Vi udnytter styrken af kognitive computing, hyper-automatisering, robotteknologi, cloud , analytics og nye teknologier til at hjælpe vores kunder med at tilpasse sig den digitale verden og gøre successfulde. En virksomhed, der er anerkendt globalt for sin omfattende portefølje af services, stærkt engagement i bæredygtighed samt virksomhedsetik , vi har over 190.000 dedikerede medarbejdere, der betjener vores kunder på seks kontinenter. Sammen kommer vi med nye ideer samt udvikler og skaber en bedre og dristig ny fremtid.
Forward-Looking Statements
The forward-looking statements contained herein represent Wipro’s beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro’s control. Such statements include, but are not limited to, statements regarding Wipro’s growth prospects, its future financial operating results, and its plans, expectations and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our business and industry. The conditions caused by the COVID-19 pandemic could decrease technology spending, adversely affect demand for our products, affect the rate of customer spending and could adversely affect our customers’ ability or willingness to purchase our offerings, delay prospective customers’ purchasing decisions, adversely impact our ability to provide on-site consulting services and our inability to deliver our customers or delay the provisioning of our offerings, all of which could adversely affect our future sales, operating results and overall financial performance. Our operations may also be negatively affected by a range of external factors related to the COVID-19 pandemic that are not within our control. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at www.sec.gov
. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210310005602/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release
CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
